{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:48:03Z","timestamp":1790300883989,"version":"4.1.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>To determine whether an exchange transfusion increases the rate of elimination\nof gentamicin, we measured drug (and bilirubin) concentration either before and\nduring, or during and after a standard two-volume exchange procedure in 7 newborns. In\nan additional 5 infants, serum was obtained only on initiation and conclusion of the procedure.\nThe mean decrement in serum gentamicin concentration with the procedure was\n2.2 \u03bcg\/ml; this was 25.7% of the original mean concentration. The mean elimination rate\nconstant during the procedure was 0.342 h^\u20131, a value significantly greater (p = 0.013) than\nthe mean rate before or after the procedure, 0.104 h^\u20131. We conclude that the exchange\ntransfusion procedure significantly increases the rate of gentamicin elimination. The decrement\nproduced by the procedure may result in subtherapeutic concentrations, if the initial\nvalues are marginally efficacious.<\/jats:p>","DOI":"10.1159\/000457445","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:38Z","timestamp":1502471318000},"page":"214-221","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Exchange Transfusion on Serum Gentamicin\nConcentrations"],"prefix":"10.1159","author":[{"given":"D.","family":"Fuquay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:15Z","timestamp":1776846855000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457445","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}